Science Writer Adaptive Biotechnologies recently received FDA Emergency Use Authorization (EUA) for T-Detect⢠COVID, a test that detects the unique T-cell signature specific to SARS-CoV-2. T-Detect COVID is the first clinical test launched from Adaptiveâs TCR-Antigen Map collaboration with Microsoft, highlighting the potential of using T cells in the blood to detect multiple diseases. To learn more about T-Detect, its development and how it compares to antibody testing, Technology Networks spoke to Dr Sudeb Dalai, senior medical director at Adaptive Biotechnologies. In this interview, Sudeb also discusses the role that T-cell analysis may play in the diagnosis and treatment of diseases in the future.